Study S003257
A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects
Registration
Registered primary outcomes
- Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473 [Baseline to day 15]
- Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473 [Baseline to day 43]
- Cmax [Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours]
- AUC [Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours]
Linked records (2)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0029053 | First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects. Zhang H, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2025 | Other trial | PMID 40175670DOI | cites ClinicalTrials.gov:NCT05943886; registry reference DERIVED:40175670 |
| R0029705 | Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study. Xiang L, Journal of hepatology | 2025 | Randomized trial | PMID 39709140DOI | cites ClinicalTrials.gov:NCT05943886; registry reference DERIVED:39709140 |